What drove IMM.AX stock activity today?

IMM.AX stock rose in volume after Immutep released positive Phase I IMP761 results and multiple investor investigations and law firm notices followed the TACTI-004 trial halt, creating heavy trading and volatility.

What is Meyka AI’s view and price forecast for IMM.AX stock?

Meyka AI rates IMM.AX **62.20/100 (B, HOLD)** and its forecast model projects **A$0.3532** in one year. Forecasts are model-based projections and not guarantees.

What are the main risks for IMM.AX stock investors?

Key risks for IMM.AX stock include binary clinical outcomes, ongoing securities investigations, limited market cap and liquidity swings, and the need for additional funding if trials continue or expand.

Which catalysts could move IMM.AX stock higher?

Potential catalysts include full Phase I IMP761 data at EULAR on 4 June 2026, clear guidance on trial wind-downs, positive regulatory interactions, or new partnerships that reduce execution risk.

AU Stocks

IMM.AX stock A$0.051, 57.80M shares on ASX: trial results and legal probes

ByDanny Kontos March 20, 2026March 20, 2026

IMM.AX stock closed at A$0.051 on the ASX on 20 Mar 2026 after 57,803,121 shares changed hands, making it one of the market’s most active small-caps today. Immutep Limited (IMM.AX) sits at a crossroads after a strong Phase I update for IMP761 and multiple investor lawsuits and investigations tied to the halted TACTI-004 trial. We summarise the trading action, clinical news, regulatory notices, and what this means for valuation and near-term catalysts using Meyka AI’s real-time market analysis platform.